Personalized dosing strategies may be necessary for biologic therapies, especially fixed-dose options like ustekinumab, due ...

Do you know what singers Cyndi Lauper and LeAnn Rimes have in common with actors Jon Lovitz and Jerry Mathers? All four are among the 7.5 million Americans who are ...

Adults with worse cardiovascular-kidney-metabolic health are at an increased risk of developing psoriasis, especially in those with high genetic risk.

Codex Labs has announced the launch of the first product in a new collection, KĀNGFÙ, that is focused on healing damaged skin ...

United States: Projected CAGR of 5.1%, with market value rising from USD 127.3 billion in 2025 to USD 209.4 billion by 2035, ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 ...

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

FDA approves guselkumab as the first IL-23 inhibitor for children 6 years or older with plaque psoriasis or psoriatic arthritis. The FDA has approved guselkumab (Tremfya; Johnson & Johnson) for the ...